Dianthus Therapeutics (NASDAQ:DNTH) Stock Rating Reaffirmed as Buy by HC Wainwright

Dianthus Therapeutics (NASDAQ:DNTH)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued on Thursday, Benzinga reports. They currently have a $158.00 target price on the stock. HC Wainwright’s price objective indicates a potential upside of 116.63% from the company’s current price.

A number of other equities analysts also recently issued reports on the stock. Wedbush upped their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Truist Financial upped their target price on Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Citigroup began coverage on Dianthus Therapeutics in a report on Friday, September 4th. They set a “buy” rating and a $156.00 target price for the company. JPMorgan Chase & Co. assumed coverage on Dianthus Therapeutics in a report on Friday, September 11th. They set an “overweight” rating and a $135.00 target price for the company. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $131.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $129.83.

Dianthus Therapeutics Stock Down 2.4%

NASDAQ:DNTH traded down $1.83 during mid-day trading on Thursday, hitting $72.94. 496,433 shares of the stock traded hands, compared to its average volume of 927,984. The stock has a market capitalization of $4.00 billion, a price-to-earnings ratio of -17.52 and a beta of 1.35. Dianthus Therapeutics has a 52 week low of $32.22 and a 52 week high of $117.88. The firm’s 50 day moving average is $100.75 and its two-hundred day moving average is $94.49.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Tuesday, August 4th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The company had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. As a group, research analysts predict that Dianthus Therapeutics will post -3.81 EPS for the current year.

Insider Activity

In related news, SVP Adam M. Veness sold 16,167 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $110.38, for a total transaction of $1,784,513.46. Following the sale, the senior vice president owned 3,833 shares in the company, valued at approximately $423,086.54. This trade represents a 80.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Simrat Randhawa sold 23,124 shares of the firm’s stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $106.41, for a total transaction of $2,460,624.84. Following the sale, the executive vice president owned 4,000 shares in the company, valued at approximately $425,640. This represents a 85.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 242,429 shares of company stock valued at $26,118,913 over the last quarter. Insiders own 3.02% of the company’s stock.

Institutional Trading of Dianthus Therapeutics

Several institutional investors have recently modified their holdings of DNTH. Assenagon Asset Management S.A. grew its holdings in Dianthus Therapeutics by 160.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 732,246 shares of the company’s stock valued at $64,474,000 after buying an additional 451,597 shares in the last quarter. Sax Wealth Advisors LLC acquired a new position in Dianthus Therapeutics in the 3rd quarter valued at about $203,000. GAMMA Investing LLC boosted its holdings in Dianthus Therapeutics by 83.6% in the 3rd quarter. GAMMA Investing LLC now owns 558 shares of the company’s stock valued at $49,000 after purchasing an additional 254 shares during the last quarter. Arizona State Retirement System boosted its holdings in Dianthus Therapeutics by 5.7% in the 2nd quarter. Arizona State Retirement System now owns 10,141 shares of the company’s stock valued at $989,000 after purchasing an additional 546 shares during the last quarter. Finally, Nykredit A S acquired a new position in Dianthus Therapeutics in the 2nd quarter valued at about $147,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing targeted antibody therapies for autoimmune diseases. The company’s approach centers on selectively modulating the complement system, an immune pathway involved in inflammation and tissue damage, with the goal of creating treatments that may offer potent disease control and convenient dosing.

Dianthus’ lead investigational product is DNTH103, a fully human monoclonal antibody designed to selectively inhibit activated C1s, a key protein in the classical complement pathway.